Vrooman Lynda M, Silverman Lewis B
Department of Pediatric Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA.
Curr Hematol Malig Rep. 2016 Oct;11(5):385-94. doi: 10.1007/s11899-016-0337-y.
While the majority of children and adolescents with newly diagnosed childhood acute lymphoblastic leukemia (ALL) will be cured, as many as 20 % of patients will experience relapse. On current treatment regimens, the intensity of upfront treatment is stratified based upon prognostic factors with the aim of improving cure rates (for those at the highest risk of relapse) and minimizing treatment-related morbidity (for lower-risk patients). Here we review advances in the understanding of prognostic factors and their application. We also highlight novel treatment approaches aimed at improving outcomes in childhood ALL.
虽然大多数新诊断的儿童急性淋巴细胞白血病（ALL）患儿和青少年能够治愈，但仍有多达20%的患者会复发。在当前的治疗方案中，初始治疗强度根据预后因素进行分层，目的是提高治愈率（针对复发风险最高的患者）并将治疗相关的发病率降至最低（针对低风险患者）。在此，我们综述了对预后因素的认识进展及其应用。我们还强调了旨在改善儿童ALL治疗结果的新型治疗方法。
